SOURCE: ScripsAmerica

ScripsAmerica

August 04, 2014 08:00 ET

ScripsAmerica's Specialty Pharmacy Receives Approved Orders of $4.1 Million in July Marking Its Fourth Consecutive Month of Sales Growth

TYSONS CORNER, VA--(Marketwired - Aug 4, 2014) - ScripsAmerica, Inc. (OTCBB: SCRC) today announced that the Company's managed specialty pharmacy reported $4,090,000 in approved orders during the month of July 2014.

July represents Main Avenue Pharmacy's fourth consecutive month of reporting record high sales. $4,090,000 marks a 51% monthly revenue increase over June and 728% increase when compared to March 2014, the first full month of pharmacy's operations while under ScripsAmerica's management. The pharmacy's annual run rate has increased to $49 million following the reporting of last month's sales.

"Scrips is pleased to announce that Main Avenue Pharmacy continues to demonstrate significant revenue growth and has consistently done so every month since we have taken over its management. We anticipate this pharmacy to continue serving as a core revenue source for our Company moving forward," stated Bob Schneiderman, ScripsAmerica's CEO. 

About ScripsAmerica, Inc.

ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information